Rain oncology stock.

View the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09.With Rain Oncology stock trading at $1.07 per share, the total value of Rain Oncology stock (market capitalization) is $38.92M.Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an …WebNovember 22, 2023. $1.07. 31,967. 1:1. $1.09. $1.09. $1.06. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits …1. Amgen (AMGN) Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen stock opened the day at $265.12 after a previous close of $264.59.

May 22, 2023. NEWARK, Calif., May 22, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and ...May 12, 2023 · Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28. What is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ...

According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.Stock Quote & Chart. Historical Price Lookup. Investment Calculator. Print Page. Email Alerts. RSS Feeds. Contact IR. Email Page. The Investor Relations website contains …

Get the latest Rain Oncology Inc. (RAIN) stock news and headlines to help you in your trading and investing decisions. The Complete List of Biotech Stocks Trading on the NASDAQ as of Nov 29, 2023 are listed below: ... Cardiff Oncology Inc. CRDF: United States: 32: Curis Inc. CRIS: United States: 33: CRISPR Therapeutics AG : CRSP: ... Rain Oncology Inc. RAIN: United States: 601: RAPT Therapeutics Inc. RAPT: United States: 602:NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...Why Shares of Rain Oncology Are Plummeting Today. Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead ...

16 Oct 2023 ... Rain Oncology, Inc. ... Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are ...

Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.Web

Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...WebNon-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...Get insightful analysis and opinion about Rain Oncology Inc (NDAQ:RAIN) and the market in general. Stockhouse Editors and other Contributors weigh in.1 Aug 2023 ... Stocks; ›; ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities ...NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...

Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53.Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...WebDiscover historical prices for RAIN stock on Yahoo Finance. View daily, weekly or monthly format back to when Rain Oncology Inc. stock was issued. Aug 10, 2023. NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our ...Stock and Other Ownership Interests: Rain Oncology Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain Oncology, Licensing fees from Takeda for Biologic Materials, Licensing fees from ...

16 Oct 2023 ... Rain Oncology, Inc. ... Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are ...

12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate …Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress ... Non-cash stock-based compensation expenses included in R&D expenses were approximately $1.1 million in the three months ended March 31, 2023, as compared to $0.9 million in the same period in 2022. General and administrative (G&A) …WebStock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc.,...1.0900. +0.0200. +1.87%. Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 ...WebFind the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.With Rain Oncology stock trading at $1.07 per share, the total value of Rain Oncology stock (market capitalization) is $38.92M.Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an …Web1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...Shares of precision oncology upstart Rain Oncology (NASDAQ:RAIN) have fallen by nearly 40% since its IPO was priced at $17 in 2021. Trailing twelve month gain is a more respectable +35%. Trailing ...

The global pharmaceutical industry is expected to generate $1.15 trillion in sales in 2023, according to Statista. The oncology segment alone should see $188.2 billion in sales this year. The ...

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress ... Non-cash stock-based compensation expenses included in R&D expenses were approximately $1.1 million in the three months ended March 31, 2023, as compared to $0.9 million in the same period in 2022. General and administrative (G&A) …Web

May 5, 2023 · Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ... Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K …On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09.Get the latest Rain Oncology Inc. (RAIN) stock news and headlines to help you in your trading and investing decisions. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.16 Oct 2023 ... Rain Oncology, Inc. ... Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are ...Rain Oncology Inc RAIN Morningstar Rating Unlock Stock XNAS Rating as of Nov 20, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...View the latest Rain Oncology Inc. (RAIN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Stocks / Pharmaceuticals & Biotech RAIN Rain Oncology NasdaqGS:RAIN Stock Report Add to watchlist Add to portfolio Last Price US$1.07 Market Cap …Stock Quote & Chart Stock Quote. Change Volume Today's Open Previous Close. Today's High ... Rain Oncology Inc. Address: 8000 Jarvis Ave Suite 204. Newark, CA, 94560Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. dss incwww.gpminvestments.comtop ten forex brokersspy open interest NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC … ely lilly stock pricegood real estate stocks Rain and other forms of precipitation occur when water accumulates in the clouds and falls to the ground. This occurs due to the water cycle, which continually recycles the water on Earth. nasdaq wkhs news Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rain Oncology, Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or …WHY: NEW YORK, NY - (NewMediaWire) - September 01, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline. SO WHAT: If …Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...